

Contents lists available at ScienceDirect

### Pharmacology & Therapeutics

journal homepage: www.elsevier.com/locate/pharmthera



### Inflammation, lipids, and pain in vulvar disease

### Megan L. Falsetta <sup>a,b,\*</sup>, Krishna Rao Maddipati <sup>c,d</sup>, Kenneth V. Honn <sup>c,d</sup>

<sup>a</sup> University of Rochester, OB/GYN Research Division, Rochester, NY, United States of America

<sup>b</sup> University of Rochester, Pharmacology and Physiology Department, Rochester, NY, United States of America

<sup>c</sup> Wayne State University, Pathology Department, Detroit, MI, United States of America

<sup>d</sup> Wayne State University, Lipidomics Core Facility and Bioactive Lipids Research Program, Detroit, MI, United States of America

#### ARTICLE INFO

Article history: Received 31 March 2023 Received in revised form 29 May 2023 Accepted 31 May 2023 Available online 5 June 2023

Associate editor: S.J. Enna

Keywords: Pain Vulvodynia SPMs Lipids TRPV4 Fibroblasts Inflammation

#### ABSTRACT

Localized provoked vulvodynia (LPV) affects ~14 million people in the US (9% of women), destroying lives and relationships. LPV is characterized by chronic pain (>3 months) upon touch to the vulvar vestibule, which surrounds the vaginal opening. Many patients go months or years without a diagnosis. Once diagnosed, the treatments available only manage the symptoms of disease and do not correct the underlying problem. We have focused on elucidating the underlying mechanisms of chronic vulvar pain to speed diagnosis and improve intervention and management. We determined the inflammatory response to microorganisms, even members of the resident microflora, sets off a chain of events that culminates in chronic pain. This agrees with findings from several other groups, which show inflammation is altered in the painful vestibule. The vestibule of patients is acutely sensitive to inflammatory stimuli to the point of being deleterious. Rather than protect against vaginal infection, it causes heightened inflammation that does not resolve, which coincides with alterations in lipid metabolism that favor production of proinflammatory lipids and not pro-resolving lipids. Lipid dysbiosis in turn triggers pain signaling through the transient receptor potential vanilloid subtype 4 receptor (TRPV4). Treatment with specialized pro-resolving mediators (SPMs) that foster resolution reduces inflammation in fibroblasts and mice and vulvar sensitivity in mice. SPMs, specifically maresin 1, act on more than one part of the vulvodynia mechanism by limiting inflammation and acutely inhibiting TRPV4 signaling. Therefore, SPMs or other agents that target inflammation and/or TRPV4 signaling could prove effective as new vulvodynia therapies.

© 2023 Elsevier Inc. All rights reserved.

#### Contents

1.	Vulvar pain	2
2.	Connections between inflammation and vulvar pain	3
3.	Lipid dysbiosis and vulvar pain	5
4.	Neuro-inflammatory mechanisms of vulvar pain	6
5.	Conclusion	8
6.	Current knowledge gaps and future directions	8
Decl	aration of Competing Interest	8
Ackı	nowledgments	8
Refe	rences	8

\* Corresponding author at: Obstetrics and Gynecology, Pharmacology and Physiology, 601 Elmwood Ave, Box 668, Rochester, NY 14642, United States of America. E-mail address: Megan\_Falsetta@URMC.Rochester.edu (M.L. Falsetta).

E mail address. Wiegan\_i alsetta@Okivie.koenestei.edu (Wi.E. 1 als

*Abbreviations:* 4xPDD, 4alpha-Phorbol 12,13-didecanoate; ADP, adenosine diphosphate; COX-2, cyclooxygenase-2; CYP450, cytochrome peroxidase 450; DHA, docosahexanoic acid; DHET, dihydroxyeicosatrienoic acid; DMSO, dimethyl sulfoxide; EET, eicosatrienoic acid; GPCR, G-coupled protein receptor; HDHA, docosahexaenoic acid; HETE, hydroxyeicosatetraenoic acid; IL-1β, interleukin-1 beta; IL-6, interleukin-1 inflammatory drugs; NFkB, nuclear factor kappa B; sEH, soluble epoxide hydrolase; SNPs, small nucleotide polymorphisms; SNRI, serotonin and norepinephrine reuptake inhibitor; SPM, specialized pro-resolving mediator; SSRI, selective serotonin reuptake inhibitor; TLR-3, toll-like receptor 3; TRPV4, transient receptor potential vanilloid subtype 4 receptor.

#### 1. Vulvar pain

Everyone with a vulva is likely to experience pain or discomfort in this area at some point in their life, even if only transiently, such as during pregnancy, after childbirth, or during menopause (Danby & Margesson, 2010; Simonelli, Eleuteri, Petruccelli, & Rossi, 2014). Despite the ubiquity of vulvar pain, our fundamental understanding of the mechanisms involved are limited, and epidemiological studies indicate it is both underdiagnosed and seldom discussed (Andrews, 2011; Bohm-Starke, 2010; Bornstein et al., 2016; Damsted-Petersen, Boyer, & Pukall, 2009; Dargie, Holden, & Pukall, 2017; Donders & Bellen, 2012; Eppsteiner, Boardman, & Stockdale, 2014; Falsetta et al., 2015; Falsetta et al., 2018; Falsetta et al., 2021; Falsetta, Foster, Bonham, & Phipps, 2017; Farmer et al., 2011; Foster et al., 2015; Groysman, 2010; Harlow et al., 2017; NIH, 2016; Pukall et al., 2016; Reed et al., 2012; Reed et al., 2014; Rosen, Dawson, Brooks, & Kellogg-Spadt, 2019; Stockdale & Lawson, 2014; Wesselmann, Bonham, & Foster, 2014; Wylie, 2017; Zanotta et al., 2018). Since the year 2000, fewer than 200 NIH grants have been funded on "vulvar pain," which includes projects focused on endometriosis and pelvic pain (Vulvar Pain [Internet] 2000-2023, 2023).

Patients with vulvar pain or sexual dysfunction often do not vocalize these concerns to their medical providers (Parish & Clayton, 2007; Rubin et al., 2018; Shindel & Parish, 2013; Solursh et al., 2003). Epidemiological studies show patients perceive their provider is not equipped to discuss topics pertaining to sexual health and many fear judgement or embarrassment (Kingsberg et al., 2019). Patient perception may reflect a limited focus on sexual medicine training in many medical school curricula (Kingsberg et al., 2019; Parish & Clayton, 2007; Rubin et al., 2018; Shindel & Parish, 2013; Solursh et al., 2003). Most patients look for providers to initiate the conversation. When these conversations do not take place, patient needs go unmet.

Yet, vulvar pain remains a common and complex problem (Harlow et al., 2014; Harlow & Stewart, 2003; Nguyen, Turner, Rydell, Maclehose, & Harlow, 2013; Reed et al., 2012; Reed et al., 2014; Reed, Harlow, Sen, Legocki, et al., 2012). It can be acute and may resolve with time or treatment, or it can be chronic (Haefner et al., 2005; Sadownik, 2014; Stockdale & Lawson, 2014). Vulvodynia is the most common cause of chronic dyspareunia (painful intercourse), affecting anywhere from 8 to 12% of women in the United States (Harlow et al., 2014; Harlow & Stewart, 2003; Reed, Harlow, Sen, Legocki, et al., 2012). Lifetime risk has been estimated even higher, suggesting that up to a third of persons with vulvas could be affected (Groysman, 2010). If a patient has chronic vulvar pain that does not resolve for at least 3 months and cannot be explained by any other cause, they usually receive a vulvodynia diagnosis (Haefner et al., 2005; Stockdale & Lawson, 2014). Vulvodynia can develop at any age and affects a large portion of reproductive age individuals. Vulvodynia destroys the patient's quality of life and has a negative impact on their relationships; it can make it difficult to sit, wear pants, ride a bicycle, use a tampon or menstrual cup, or engage in sexual activity (Haefner et al., 2005; Jeon et al., 2013; Kingdon, 2009; NIH, 2016; Nunns et al., 2010; Pukall et al., 2016; Reed, Harlow, Sen, Edwards, et al., 2012; Sadownik, 2014; Stenson, 2017; Stockdale & Lawson, 2014; Wesselmann et al., 2014). Because vulvodynia is a diagnosis of exclusion, patients suffer months to years before a diagnosis. Once diagnosed, treatment is often "trial and error," escalating from less to more invasive and often culminating in surgical procedures to remove the affected tissue, essentially amputating a portion of the vulva.

The most common type of vulvodynia is localized provoked vulvodynia (Akopians & Rapkin, 2015; Bohm-Starke, 2010; Falsetta et al., 2015; Falsetta et al., 2015; Falsetta et al., 2013; Falsetta et al., 2021). This is pain that occurs upon touch (mechanical allodynia) and is localized to the vulvar vestibule, or ring of tissue surrounding the vaginal opening. Adjacent areas are non-painful to touch, while the vestibule is extremely sensitive, particularly between the 5 and 7-o'clock positions (Fig. 1). Removal

of this tissue during a surgical procedure termed a vestibulectomy is often curative and carries over a 90% satisfaction rate (Andrews, 2011; Rosen et al., 2019; Stenson, 2017; Tommola, Unkila-Kallio, & Paavonen, 2010; Tommola, Unkila-Kallio, & Paavonen, 2011; Tommola, Unkila-Kallio, & Paavonen, 2012; Wu, Goldstein, Klebanoff, & Moawad, 2019). However, due to its invasive nature and inherent risk, vestibulectomy is often delayed until all other treatments fail.

Treatment for vulvodynia is trial and error (Danby & Margesson, 2010; Eppsteiner et al., 2014; Falsetta et al., 2017; Fischer, 2004; Haefner et al., 2005; Kingdon, 2009; Nunns et al., 2010; Rosen et al., 2019; Sadownik, 2014; Spoelstra, Dijkstra, van Driel, & Weijmar Schultz, 2011; Stenson, 2017; Stockdale & Lawson, 2014; Tieu & MacGregor, 2011; Tommola et al., 2010; Wesselmann et al., 2014; Wu et al., 2019), usually beginning with conservative management, including use of hypoallergenic soaps and lotions, wearing exclusively cotton undergarments, and avoiding wearing tight clothing or causing friction to the affected area. Most patients then move onto topical therapies, such as lidocaine, which is applied to the area before inserting anything into the vagina. This can be helpful, but it only temporarily reduces sensation in the area and can be transferred to the partner during intercourse. Gabapentin, selective serotonin reuptake inhibitors (SSRIs), and serotonin and norepinephrine reuptake inhibitor (SNRIs) are the next line, sometimes applied topically or injected, but typically dosed orally. Patients may try botulinum toxin injection into the area, which is thought to act on substance P to reduce pain. Patients also engage in cognitive behavioral therapy, bio-feedback, mediation and mindfulness, and relationship, psychiatric, or sexual counseling. When these fail, eligible patients usually elect vestibulectomy.

Vulvodynia can be further sub-divided into categories based on clinical presentation, but little to no mechanistic, scientific, or biological evidence is available to distinguish these categories (Bornstein et al., 2016; Eppsteiner et al., 2014; Falsetta et al., 2017; Haefner et al., 2005; Stockdale & Lawson, 2014). Patients may have generalized vulvodynia, where the entire vulva is affected, making them ineligible for surgery. Patients can also have unprovoked or spontaneous pain. Patients can have primary or secondary vulvodynia, referring to whether they experienced a pain-free intercourse period before developing pain (secondary) or whether pain was experienced at the first attempt at tampon use or intercourse (primary). Because there is limited scientific information, it is difficult to discern if these presentations are manifestations of the same disease or unique disease entities. Clearly, there are knowledge gaps, leading to treatment delays and failures and an overall poor quality of life in vulvodynia patients. Although there is some evidence to support the use of any approved vulvodynia therapy, there is no level



**Fig. 1.** Anatomy of Localized Provoked Vulvodynia. Pain is usually located at the posterior part of the vulvar vestibule between 5 and 7-o'clock (red shading). The numbers orient the clock with the 12-o'clock position near the clitoris.

1 evidence for their use, meaning most treatments have not been demonstrated more effective in blinded randomized control trials. More recently, our group and others have begun to unravel the biological mechanisms at play in vulvodynia with a focus on developing more effective mechanism-based therapies through the use of cellular and mouse models of disease (Akopians & Rapkin, 2015; Baker, Peresleni, & Kocis, 2016; Barry, Matusica, & Haberberger, 2019; Falsetta et al., 2015; Falsetta et al., 2016; Falsetta et al., 2017; Falsetta et al., 2018; Foster et al., 2007; Foster et al., 2015; Leclair et al., 2011; Leclair, Leeborg, Jacobson-Dunlop, Goetsch, & Morgan, 2014; Reed et al., 2018; Tommola et al., 2016; Tommola, Butzow, Unkila-Kallio, Paavonen, & Meri, 2015; Zanotta et al., 2018).

#### 2. Connections between inflammation and vulvar pain

#### 2.1. Yeast infections and vulvodynia

In patients with secondary vulvodynia, which appears more common than primary vulvodynia, there is a tipping point where patients go from pain-free to painful intercourse (Bornstein et al., 2016; Falsetta et al., 2017; Fischer, 2004; Haefner et al., 2005; Stockdale & Lawson, 2014). The most common warning sign is the occurrence of transient bouts of pain immediately following intercourse. It is difficult to discern a clear environmental cause for vulvodynia, as patients recall numerous factors that could have precipitated their pain, including sexual assault, vulvovaginal infections, childbirth, injury, abuse, trauma, and more (Arnold, Bachmann, Rosen, Kelly, & Rhoads, 2006; Reed et al., 2014; Reed, Harlow, Sen, Edwards, et al., 2012; Reed, Harlow, Sen, Legocki, et al., 2012). However, the most common precipitating factor cited by >70% of patients is a previous history of chronic or recurrent yeast infection (Donders & Bellen, 2012). Patients recall experiencing a yeast infection that never fully cleared or 4 or more yeast infections in the past year. It is important to note that the majority of yeast infections are self-diagnosed and treated with over-the-counter antifungals (Hani, Shivakumar, Vaghela, Osmani, & Shrivastava, 2015; Lipsky & Taylor, 1996; Mendling et al., 2012). Few patients undergo laboratory testing. Therefore, it is possible that other agents, such as bacteria, viruses, or irritants could play a role.

There is strong evidence from patients, human cells, and animal studies to implicate yeast, especially Candida albicans, in the onset of vulvodynia. C. albicans is among the most common agents that cause vulvovaginal yeast infection (Farmer et al., 2011; Giraldo et al., 2000; Peters et al., 2014). Other non-albicans Candida, such as C. glabrata and C. tropicalis come in close second. Patients with vulvodynia can show cutaneous hypersensitivity to C. albicans, similar to an allergic reaction, suggestive of an overall sensitivity to this yeast species (Ramirez De Knott et al., 2005). Human fibroblasts taken from painful areas of the vestibule of localized provoked vulvodynia (LPV) patients also show a hypersensitivity to yeast, where <100 yeast cells elicit an inflammatory response characterized by elevated levels of interleukin-6 (IL-6) and prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) (Falsetta et al., 2015). Patients with vulvodynia do not have active yeast infections at the time of diagnosis (Haefner et al., 2005; Stockdale & Lawson, 2014); this data provides evidence that a small number of yeast, which are beneath the clinical limit of detection, can cause a significant inflammatory response in painful areas of the vestibule. This response is specific to the painful area of the vestibule and does not occur in cells taken from an adjacent non-painful site in the external vulva, which require numbers of yeast commiserate with an active infection to elicit a response (Falsetta et al., 2015). Fibroblasts from the painful vestibule also show enhanced sensitivity to C. glabrata, C. tropicalis, Saccharomyces cerevisiae, and zymosan, a yeast cell wall extract from Saccharomyces, compared to non-painful sites in the patient and from the same anatomical sites in patients without vulvodynia (Foster et al., 2015). Furthermore, repeated vulvovaginal infection with C. albicans or injection of zymosan into the vulva of several mouse strains (e.g. CD-1, BALB/c,

and C57/BL-6) results in persistent sensitivity to touch (up to 16 weeks), while animals receiving saline remain insensitive (Falsetta et al., 2021; Farmer et al., 2011).

#### 2.2. Inflammation and vulvar fibroblasts

We developed a fibroblast model for studying vulvodynia where each patient serves as their own control by taking 6 mm biopsies from both the painful vestibule and external non-painful vulva (Fig. 2). Biopsies are collected during a scheduled vestibulectomy for LPV patients and during another gynecologic surgery in patients without a history of vulvar disease (controls), which minimizes patient discomfort and infection risk. Each biopsy tissue can then be partitioned into up to 3 individual pieces for development of primary fibroblast stains and other approaches, such as histology, proteomics, transcriptomics, and lipidomics (Fig. 2). This design facilitates paired analysis and allows for the comparison of painful to non-painful areas in both cases and controls to pinpoint what is happening at the painful vulvar vestibule. The high satisfaction rate with vestibulectomy (Tommola et al., 2010; Tommola et al., 2011; Tommola et al., 2012) supports the hypothesis that there is something unique about the vestibule that can lead to chronic pain.

Pursuant to the possible connection between vulvovaginal yeast infection and vulvodynia, we introduced live yeast infection into our model and found that fibroblasts from the painful vestibule are indeed more sensitive to yeast than non-painful areas from cases and controls, measured by IL-6 and PGE<sub>2</sub> production (Falsetta et al., 2015; Foster et al., 2015). Furthermore, we determined the response of fibroblasts to *C. albicans* could predict the patient threshold at the site from which the fibroblasts were obtained (Foster et al., 2015). This finding 1) implicates inflammation in the vulvodynia mechanism, 2) demonstrates that the model correlates with key patient measures, and 3) establishes IL-6 and PGE<sub>2</sub> as surrogate measures of pain, facilitating high through-put mechanistic studies that are impossible to conduct in the patient.

We considered the mechanisms by which fibroblasts might recognize yeast, focusing on recognition of conserved pathogen-associated molecular patterns (PAMPs) by host pattern recognition receptors (PRRs). Based on the chronicity of pain, we initially focused on PRRs involved in recognizing  $\beta$ -glucan, a key component of the *C. albicans* biofilm matrix associated with chronic infection (Alves et al., 2014; Chaffin, 2008; Harriott, Lilly, Rodriguez, Fidel Jr., & Noverr, 2010; Nett, Sanchez, Cain, & Andes, 2010; Taff et al., 2012). We later expanded our scope to toll-like receptors (Falsetta et al., 2018), which can recognize specific components of the yeast cell, as well as bacteria and viruses (Bourgeois & Kuchler, 2012; Doyle & O'Neill, 2006; Gow, van de Veerdonk, Brown, & Netea, 2012). We also looked at bradykinin receptors (Falsetta et al., 2016), which are not PRRs, but are involved in pain signaling. All the receptors studied were determined to be significantly more highly expressed in the painful vestibule compared to non-painful sites, likely accounting for enhanced sensitivity to C. albicans (Falsetta et al., 2015; Falsetta et al., 2016; Falsetta et al., 2017; Falsetta et al., 2018; Falsetta et al., 2021).

We found that sensitivity to inflammatory stimuli was also elevated in the vestibule of patients without vulvodynia albeit to much lesser extent (Falsetta et al., 2015; Falsetta et al., 2016; Falsetta et al., 2017; Falsetta et al., 2018; Falsetta et al., 2021). These findings suggest that pain in the vestibule may be an extreme of a normally protective response to inflammatory stimuli (Fig. 3). Considering the physical location of the vestibular tissue and its unique embryonic origin, it makes sense that the vestibule serves as a protective barrier to vaginal infection, much like a moat around a castle (Chadha et al., 1998; Farage & Maibach, 2006; Friedrich Jr., 1983). This exaggerated response is deleterious and could explain the evolution of chronic pain, one of the cardinal symptoms of inflammation (*dolor*).

Knocking down or impairing the function of any one receptor reduces the response to inflammatory stimuli, but does not ablate this



Fig. 2. LPV Model. 6 mm punch biopsies are collected during surgery from both LPV cases and from healthy controls (no vulvar disease). These are then sectioned into 3 pieces, each for a specific type of analysis, namely fibroblast isolation and culture, analysis of gene expression, and quantification of lipid profiles. An n of 1 represents 4 tissue samples, with only one painful sample from the vestibule of a case, while the remaining 3 samples, whether from case or control, are from non-painful areas of the vestibule and external vulva.

response (Falsetta et al., 2015; Falsetta et al., 2016; Falsetta et al., 2017; Falsetta et al., 2018). Consistent with the literature, we determined activation of these receptors in turn triggers nuclear factor kappa B ( $NF\kappa B$ ) signaling in vulvar fibroblasts (Doyle & O'Neill, 2006; Gantner,

Simmons, Canavera, Akira, & Underhill, 2003; Lawrence, 2009; Luqman & Pezzuto, 2010). Blocking NFkB activity using Bay-11–7082 ablates inflammatory mediatory production in vestibular fibroblasts, pointing to NFkB as a master regulator of inflammation in vulvodynia



**Fig. 3.** *Inflammatory Mechanisms of Vulvodynia*. In patients with localized provoked vulvodynia, an abberation of a normally protective response against infection is exeracerbated by the elevated expression and function of nearly a dozen different receptors involved in innate immune responses (dectin-1, TLRs) and pain signaling (bradykinin receptors). This significantly increases levels of IL-6 and PGE<sub>2</sub>, which has been associated with pain in vulvodynia. On the left side, healthy controls are depicted, which express normal levels of receptors, responding only to infectious threats, which subsequently triggers immune clearance, after which inflammation resolves. On the right, LPV cases express abnormally high levels of receptors and associated with pain.

(Falsetta et al., 2015; Falsetta et al., 2016; Falsetta et al., 2017; Falsetta et al., 2018). Based on the link between inflammatory mediator production in fibroblasts and pain in the patient, reducing IL-6 and PGE<sub>2</sub> is likely to have analgesic properties. However, the connection between inflammation and pain in vulvodynia warrants further investigation. While IL-6 and PGE<sub>2</sub> are surrogate measures of pain, an animal model of vulvodynia was necessary to quantify sensitivity indicative of pain.

#### 2.3. Rodent models of vulvar allodynia

One potential barrier to the development of novel therapeutics is the need for preclinical models of disease. There are a few rodent models of vulvar pain that use allergens or irritants (e.g. haptens, oxazolone, streptozotocin, and methylisothiazolinone) to provoke vulvar sensitivity, but it is unclear if these exposures model any natural causes of vulvodynia (Akbar et al., 2016; Ali et al., 2015; Aman et al., 2016; Arriaga-Gomez et al., 2019; Awad-Igbaria et al., 2022; Boo et al., 2019; Pierce et al., 2015; Rangappa, Shankar, Jo, Repka, & Murthy, 2021). In a model developed by Farmer et al. mice were infected vulvovaginally with C. albicans or zymosan was injected into the midline vulvar skin immediately posterior to the vaginal opening (Farmer et al., 2011). Farmer determined vulvovaginal exposure to yeast or yeast products resulted in sustained allodynia, similar to what is observed in LPV patients. This is a key piece of evidence supporting the hypothesis that chronic yeast infection incites vulvar pain. However, the Farmer model was not designed to test therapeutic interventions. Therefore, we worked to expand the model to improve reproducibility, investigator comfort and reliability, and create a sustained window of stable allodynia (~16 weeks) for traditional pharmacokinetic testing (Falsetta et al., 2021).

The disease pattern in our model is similar to human allodynia; there is a clear inflammatory response during the induction phase in mice receiving zymosan injections (Falsetta et al., 2021). After the first few weeks, the response tapers off and there is no active inflammatory response at the time of treatment, while mice remain exquisitely sensitive to touch (< 1 g force elicits a response). Congruent with the role of inflammation in LPV, we found that interrupting this process via twice daily topical application of the specialized pro-resolving mediator (SPM) maresin 1 increased sensitivity thresholds to pre-induction baselines in <4 weeks, effectively alleviating pain. SPMs are small lipids involved in the resolution of inflammation. Unlike steroids or non-steroidal anti-inflammatory drugs (NSAIDs), SPMs do not risk compromising immune defense at a site that must respond to environmental threats (Serhan, 2017a; Serhan, Chiang, Dalli, & Levy, 2014). Rather, SPMs help to resolve inflammation faster and more efficiently, helping restore homeostasis, clear infection, and heal wounds (Buckley, Gilroy, & Serhan, 2014; Buckley, Gilroy, Serhan, Stockinger, & Tak, 2013; Chiurchiu et al., 2016; Cianci et al., 2016; Croasdell et al., 2015; Dakin et al., 2019; Fonseca, Orlando, Turchetti-Maia, & de Francischi, 2017; Levy & Serhan, 2014; Serhan, 2014; Serhan, 2017a; Serhan, 2017b; Serhan et al., 2014; Serhan, Chiang, & Dalli, 2015; Serhan, Chiang, & Dalli, 2018). There is a growing body of evidence to support their use as analgesic agents (Falsetta et al., 2021; Luo, Gu, Tao, Serhan, & Ji, 2019; Serhan et al., 2012; Tao, Lee, Donnelly, & Ji, 2020; Zhang et al., 2018). SPMs are naturally produced, safe, and do not result in dependence.

#### 3. Lipid dysbiosis and vulvar pain

#### 3.1. Why do the symptoms of vulvodynia persist?

For a long time, the resolution of inflammation was thought to be an inactive process mediated by a progressive tapering off of inflammatory signals as infection resolves and immune cells lyse and are no longer recruited to the site of infection (Buckley et al., 2014; Chiang & Serhan, 2017; Chiang & Serhan, 2020; Serhan, 2017a; Serhan, 2017b; Serhan et al., 2014; Serhan et al., 2015). However, with the discovery of SPMs,

it became apparent that resolution is an active process governed by the secretion of lipid mediators that have specific and profound effects on immune cells that foster immune clearance and the return to homeostasis. The balance between resolution and inflammation has sometimes been referred to as a "Goldilocks mechanism" where everything needs to be "just right" to ensure resolution is sufficient but not overzealous. As discussed, in LPV, there is a heightened response to inflammatory stimuli in the vulvar vestibule, which represents an extreme of a naturally protective response (Fig. 3). However, this does not explain why resolution fails to quell this deleterious response nor how inflammation leads to vulvar allodynia.

The chronicity of inflammation led us to hypothesize that a defect in the resolution machinery could account for unresolved inflammation. Therefore, we elected to use targeted lipidomic analysis to quantify the abundance of lipids involved in both resolution and inflammation in vulvar tissues collected from LPV patients and healthy controls. Punch biopsies from painful sites in the vestibule and non-painful sites in the external vulva of LPV patients were analyzed along with matched biopsies from controls. One-third of each 6 mm biopsy was used for lipidomic analysis from a total of 10 case and 10 control patients. Three lipids implicated in resolution (12- hydroxyeicosatetraenoic acid (HETE), 8(9)eicosatrienoic acid (EET), and 14(15)-EET) were found to be highly and significantly reduced in the painful vestibule compared to non-painful areas from both cases and controls (Maddipati, 2020; Thomson, Askari, & Bishop-Bailey, 2012; Yu et al., 2000). We also observed concomitant increases in lipids involved in inflammation, such as PGE<sub>2</sub>. These findings indicated that there may be a deficit in the resolution machinery that accounts for the chronicity of inflammation. We therefore hypothesized that adding exogenous SPMs could overcome this deficit by compensating for the reduction in pro-resolving lipids. We elected to focus on SPMs, because our pilot experiments indicated they were reduced in vulvodynia patients, are already under development for human use, and likely effective at lower doses than their precursor lipids (e.g. 8(9)-EET).

#### 3.2. Pro-resolving mediators reduce inflammation and vulvar pain

We used our fibroblast model to screen commercially available SPMs across a variety of dosages and dosing strategies in cells from both painful and non-painful areas (Falsetta et al., 2021). We first explored a pretreatment model of vulvodynia, where we treated cells with the SPMs, then initiated inflammation using recombinant human interleukin-1ß (IL-1B). IL-1B, an endogenous inflammatory stimulus, elicits a predictable and reproducible response, making it a useful tool for inducing inflammatory responses in human fibroblasts (Falsetta et al., 2015; Falsetta et al., 2016; Falsetta et al., 2018; Falsetta et al., 2021; Foster et al., 2015). Although, there are no laboratory tests for vulvodynia at present, it is our goal to identify an LPV lipid signature using targeted lipidomics. This signature could be used to screen asymptomatic patients and intervene before the onset of pain and comorbid conditions linked to pain. It could also be used as an objective clinical trial measure or clinical metric by which to assess the progression and remission of symptoms. Early screening and prevention could be used in patients with warning signs, such as a family history of vulvodynia or someone who is experiencing transient bouts of pain following intercourse. Vulvodynia may be heritable (Goldstein et al., 2014; Jeremias, Ledger, & Witkin, 2000; Kalfon et al., 2019; Morgan et al., 2016; Reed, Harlow, Plegue, & Sen, 2015). This signature might also prove useful in establishing biological classifications of disease to help better define our current clinical classifications (e.g. provoked vs. unprovoked).

Using the prevention strategy, we were able to significantly attenuate the production of IL-6 and PGE<sub>2</sub> in response to IL-1 $\beta$  for most, but not all SPMs (Falsetta et al., 2021). Resolvin D1, aspirin triggered resolvin D1, and the precursor of resolvin D1 (17S-hydroxy docosahexaenoic acid, HDHA) were generally not successful in reducing mediator levels, while the others were highly effective in reducing IL-6 and many also reduced PGE<sub>2</sub>. Therefore, we elected to try a treatment strategy, which is currently the most likely scenario as patients present with symptoms for a duration >3 months. Our results for the treatment strategy were comparable; most SPMs reduced IL-6 and several also reduced PGE<sub>2</sub>. This gave us a list of SPMs with greatest potential for reduction of inflammation in vulvodynia, which included maresin 1, lipoxin A<sub>4</sub>, and resolvin D<sub>2</sub>.

Before moving to testing analgesia in mice, we first determined that the mouse vulva both produces SPMs and expresses the majority of the G-coupled protein receptors (GPCRs) that recognize various SPMs. We also determined that explants of mouse vulvar tissue cultured as 3D tissue biopsies were highly responsive to maresin 1, lipoxin A<sub>4</sub>, and resolvin D<sub>2</sub>, demonstrated through their ability to reduce PGE<sub>2</sub> (Falsetta et al., 2021). Of the three, maresin 1 reduced PGE<sub>2</sub> to the greatest magnitude, placing maresin 1 as a front runner for future drug development.

We went on to test the analgesic effects of maresin 1 and docosahexanoic acid (DHA) in our mouse model of vulvodynia (Falsetta et al., 2021). DHA, a dietary polyunsaturated fatty acid, is a precursor for maresin synthesis. Maresin 1 was highly effective in returning sensitivity thresholds to their starting baselines. In models of tactile or mechanical allodynia, a von Frey probe is used to measure the tolerance to pressure, as is done clinically to determine thresholds in humans. The greater the force withstood without withdrawal, the lower the sensitivity. Mice with high sensitivity will react and withdraw or evade the probe with little to no force applied. Mice receiving maresin 1 recovered to and exceeded their starting baseline after 4 weeks of twice-daily treatment weekdays and once-daily treatment on weekends. Mice receiving vehicle also recovered during this period, but not to the magnitude of those receiving maresin 1 and did not exceed baseline. Mice that did not develop allodynia that received maresin 1 showed no significant difference in their thresholds compared to baseline. The vehicle contained dimethyl sulfoxide (DMSO), which has analgesic properties on its own (Morris, 1966). Although this may not be ideal for detecting differences in a laboratory experiment, any benefit added by the vehicle would be welcome in a clinical application. This data demonstrated that SPMs have a high potential for therapeutic translation in humans; clinical trials will be necessary to move forward. Currently, it is unclear whether chronic SPM treatment would be needed to maintain its effects in humans. Mice recover completely after a short duration of treatment, but this remains to be tested in vulvodynia patients. Although SPMs represent a promising avenue for therapeutic development, this did not explain the cause for this deficit, nor how inflammation might elicit pain in the vulva.

#### 4. Neuro-inflammatory mechanisms of vulvar pain

# 4.1. Pools of lipids involved in pain signaling are sustained in the painful vestibule

In exploring the mechanisms responsible for deficiencies in proresolving lipids using a targeted lipidomic analysis panel comprised of ~150 pro-resolving and inflammatory mediators, we made an unexpected finding. There are 4 EETs that are implicated in resolution: 5 (6)-EET, 8(9)-EET, 11(12)-EET, and 14(15)-EET (Thomson et al., 2012; Yu et al., 2000). Since half of these were significantly less abundant in the painful vestibule, we became interested in their metabolism. EETs are produced by members of the cytochrome peroxidase (CYP) 450 family from the polyunsaturated dietary fatty acid arachidonic acid (Hammock et al., 2021; Pearson, Warren, Barrett, & Khan, 2009). EETs can be broken down to their less active, but not completely inactive dihydroxyeicosatrienoic acid (DHET) forms by an enzyme known as soluble epoxide hydrolase (sEH) (Hammock et al., 2021; Pearson et al., 2009; Thomson et al., 2012; Yu et al., 2000). Previous studies have shown that inhibiting sEH can have pro-resolving and even analgesic properties by reducing EET degradation and thus maintaining EET pools (Hammock et al., 2021; Thomson et al., 2012; Yu et al., 2000). Therefore, we wanted to determine if EET levels were reduced in the painful vestibule because of enhanced sEH degradation or reduced production by CYP450. Our lipidomic analysis also measured DHETs, which allowed us to calculate a ratio of active EET over inactive DHET for each of the 4 EETs. We anticipated a decrease in this ratio for at least 8(9)-EET and 14(15)-EET based on their reduced abundance in the painful vestibule. However, only one EET ratio showed a significant difference, which was 5(6)-EET. Surprisingly, 5(6)-EET active pools were *enhanced* in the painful vestibule, which appeared to be the result of a reduction in the 5(6)-DHET breakdown product. However, our lipidomic screen does not measure other metabolites of 5(6)-EET, and sustained DHETs levels do not preclude the involvement of sEH.

5(6)-EET is exceedingly short-lived and difficult to measure (Zosmer, Elder, & Sullivan, 2002). Therefore, its sustained presence in the painful vestibule was noteworthy. Although there is empiric evidence for the role of 8(9)-EET, 11(12)-EET, and 14(15)-EET in resolution (Thomson et al., 2012; Yu et al., 2000), there are no publications that demonstrate such a role for 5(6)-EET. The most established role for 5(6)-EET is activation of the transient receptor potential vanilloid subtype 4 receptor implicated in pain signaling, specifically mechanical allodynia (Berna-Erro et al., 2017). Although inflammation is related to pain, this was the first evidence for enhanced pain signaling in the vestibule of LPV patients suggestive of a neuro-inflammatory mechanism. However, the relationship between inflammation, lipids, and TRPV4 signaling would prove to be even more complex than we initially hypothesized.

#### 4.2. TRPV4 signaling is elevated in painful areas and fed by inflammation

We next determined that 1) TRPV4 is more highly expressed in the painful vestibule, and 2) knocking it down reduces inflammatory mediator production in vulvar fibroblasts. Heightened receptor expression (TRPV4) combined with heightened levels of the receptor ligand (5 (6)-EET) could lead to enhanced pain signaling. However, the relationship with inflammation was less clear. We hypothesized that activation of TRPV4 would foster increases in PGE<sub>2</sub> and IL-6, which is consistent with the literature. TRPV4 activation often increases inflammatory mediator production through activation of downstream inflammatory pathways (Ito et al., 2017; Kaneko & Szallasi, 2014; Mickle, Shepherd, & Mohapatra, 2015; Moore, Gupta, Jordt, Chen, & Liedtke, 2018; Moran & Szallasi, 2018; Poole et al., 2013; Wang et al., 2011). Therefore, we challenged vulvar fibroblasts with increasing concentrations of the TRPV4 synthetic activator 4alpha-Phorbol 12,13-didecanoate ( $4\alpha$ PDD) expecting to see concomitant increases in PGE<sub>2</sub> and IL-6. However, even the highest doses of  $4\alpha$ PDD, which showed some cellular toxicity, did not increase levels over the vehicle control. This was surprising, but it fit with other observations that  $4\alpha$ PDD was unable to activate calcium flux in fibroblasts, while they were responsive to the positive controls adenosine diphosphate (ADP) and histamine. TRPV4 is a non-specific cation channel that is permeable to calcium (Darby, Grace, Baratchi, & McIntyre, 2016; Vriens et al., 2005). Measuring intracellular calcium is a convenient and sensitive measurement of calcium flux through the channel.

In taking a step back, we realized that we were missing a key element necessary to best model vulvodynia, which was ongoing inflammation. In vulvodynia, patients appear to have chronic, low levels of inflammation that likely play a role in pain. Therefore, we pre-treated cells with IL-1 $\beta$  overnight before challenging with 4 $\alpha$ PDD for our calcium flux experiments. We found that with IL-1 $\beta$  pre-treatment, cells responded to 4 $\alpha$ PDD, even at the lowest dose. When we simultaneously treated cells with IL-1 $\beta$  and increasing doses of 4 $\alpha$ PDD, we saw a dramatic increase in IL-6 and PGE<sub>2</sub> levels, which were up to 5-fold higher than in cells treated with IL-1 $\beta$  alone. Altogether these results indicate concomitant inflammation is required for TRPV4 signaling to proceed in vulvar fibroblasts. Because levels of IL-6 and PGE<sub>2</sub> could be reduced

with an inhibitor of TRPV4 (HC064047) without any added 4 $\alpha$ PDD, we wondered if inflammation alone was sufficient to initiate calcium signaling. We found that IL-1 $\beta$  (endogenous stimulus) and Poly(I:C), an exogenous stimulus that mimics viral RNA, could initiate calcium flux without an activator of TRPV4, indicating inflammation is both necessary and sufficient for TRPV4 signaling. In addition, we determined that TRPV4 activity is highest in the painful vestibule in response to 4 $\alpha$ PDD, Poly(I:C), and the natural activator, 5(6)-EET, suggesting that changes in lipid profiles in the vulvar vestibule play a role in disease.

# 4.3. Inflammation induces changes in lipid profiles fostering inflammation and TRPV4 signaling

To investigate how inflammation influences the vulvar lipidome, we treated fibroblasts with IL-1 $\beta$ , Poly(I:C), or vehicle. We found that lipids involved in the resolution of inflammation (e.g. lipoxin B<sub>4</sub>, maresin 1, EETs) were significantly reduced in the painful vestibule of cells treated with endogenous or exogenous inflammatory stimuli. At the same time, lipids involved in inflammation (e.g. prostaglandins, leukotrienes) increased with inflammatory stimulation. The greatest degree of change occurred with Poly(I:C) treatment, suggesting that cells are more responsive to exogenous stimuli, consistent with the idea that chronic vulvovaginal infection precipitates vulvodynia symptoms. Poly(I:C) stimulates toll-like receptor 3 (TLR-3), which is more highly expressed in the painful vestibule and is involved in the recognition of nucleic acids from various microorganisms (Chiba et al., 2013; Falsetta et al., 2018). As discussed earlier, yeast infections have been implicated in the onset of vulvodynia, although most yeast infections are not diagnosed clinically. The TLR receptors, which are involved in the inflammatory response in vulvodynia, recognize yeast cells and their products, but they also recognize bacteria and viruses (Bourgeois & Kuchler, 2012; Doyle & O'Neill, 2006; Falsetta et al., 2018; Gow et al., 2012). Therefore, it is unclear if yeast species are the causative agent or whether there are other triggers. This is an area of current investigation. Nonetheless, inflammatory stimuli clearly alter lipid profiles in the painful vestibule, which favors inflammation and TRPV4 pain signaling, while reducing the resolution capacity, as evidenced by reductions in pro-resolving lipids in vestibular tissue and fibroblasts. The combination of heightened inflammatory responses to even the resident microbiota and a defect in the ability to quell this response, which is linked pain signaling, represents the "perfect storm," eliciting chronic low levels of inflammation and pain in LPV patients. Targeting TRPV4 with HC067047 reduces inflammatory signaling, suggesting targeting TRPV4 could be another option for therapeutic development.

# 4.4. Treatment strategies structured around the known vulvodynia mechanism

Reducing inflammation and enhancing resolution through the application of SPMs and their precursors appears to be a viable treatment strategy for vulvodynia, especially given the profound analgesic properties of maresin 1 and DHA (Falsetta et al., 2021). We have also explored the use of fish oils that are naturally enhanced for DHA and intermediates of SPM synthesis, such as 14-HDHA. These too are highly effective in reducing signs of pain in mice with vulvar allodynia. Whether this will translate to significant effects in humans remains to be seen. However, there is good reason to believe translation is likely. The use of a natural product could lead to faster implementation; SPMs cannot be purified in sufficient quantities from dietary sources, warranting chemical synthesis and FDA-regulated drug development steps.

In exploring the TRPV4 pathway, we became curious as to whether maresin 1 would impact TRPV4 signaling; SPMs, especially resolvins, have been shown to reduce the activity of closely related TRPV1 (Bang et al., 2010; Bang, Yoo, Yang, Cho, & Hwang, 2012; Jo, Lee, & Park, 2016; Luo et al., 2019; Park et al., 2011; Payrits et al., 2020; Serhan et al., 2012). TRPV1 recognizes capsaicin, the spicy component in chili peppers, and has been implicated in peripheral neuropathy pain (Kaneko & Szallasi, 2014; Mickle et al., 2015; Moore et al., 2018; Moran & Szallasi, 2018). We found that maresin 1 was able to impede TRPV4 signaling on the order of seconds, demonstrating an acute effect. This helps to explain maresin's impressive pain-reducing capacity in our mouse model; it can quell the inflammation that is necessary to elicit TRPV4 signaling *and* it can act on TRPV4 acutely. Maresin 1, and possibly other SPMs, act on multiple parts of the established LPV mechanism. We



Fig. 4. Neuro-inflammatory Mechanism of Vulvodynia and Proposed Action of Maresin 1. Abberant responses to inflammatory stimuli, as a result of heightened expression of receptors involved in innate immune recognition and a subsequent failure to resolve these responses due to reduced pro-resolving mediator levels, leads to chronic inflammation and changes in lipid profiles that favor the activation of the TRPV4 pain signaling pathway. When TRPV4 is activated, inflammatory mediators are further elevated, and TRPV4 expression is up-regulated, creating a feed-forward loop that amplifies inflammatory and pain signals. Much like a snowball rolling down a hill (depicted by the blue circle with snowflake sympsion), this feed-forward loop gains momentum leading to a failure to resolve inflammation and thus sustained pain signaling. Application of SPMs, specifically maresin 1, inhibits several aspects of this mechanism, which is denoted by the red arrows. Maresin 1 application would thus significantly attenuate the feed-forward loop and reduce the size of or eliminate the "snowball."

have found that inflammatory signaling helps to increase the expression of TRPV4, while TRPV4 activation results in the augmentation of inflammatory signaling. This represents a feed-forward loop causing amplification of the signals involved in inflammation and pain signaling, much like a snowball rolling down a hill. Maresin 1 is able to reduce the size of the snowball by both quelling inflammation and inhibiting TRPV4 signaling (Fig. 4).

Although, we have thus far only scratched the surface of the LPV mechanism, we have identified a class of molecules with high therapeutic capacity, which offer almost no toxicity as they are naturally produced or based on naturally produced molecules. As we continue to investigate the mechanism, we are likely to identify other analgesic targets. However, SPMs may show superior pain-relieving capacity as they act on more than one part of the pathway. We have identified other therapeutic options that could involve the use of off-label therapies such as antifungals, which also target CYP450 (Kjaerstad et al., 2010) and may reduce 5(6)-EET levels, or NSAIDs that target cyclooxygenase-2 (COX-2) and thus the production of PGE<sub>2</sub> (Kawabata, 2011). Even diet modification to reduce sources of arachidonic acid synthesis could be another possibility, especially given that there is some evidence for the benefits of a low oxalate diet in vulvodynia, which is naturally low in sources of linoleic acid, from which arachidonic acid is produced (Greenstein et al., 2006; Harlow, Abenhaim, Vitonis, & Harnack, 2008). Improved understanding of the biological mechanisms that precipitate and sustain vulvodynia symptoms will only serve to enhance the odds of identifying promising new therapeutic avenues.

#### 5. Conclusion

There is considerable work to be done, but SPMs show promise for the development of new therapeutics for LPV. They are safe and naturally produced, although drug development steps are necessary for chemically synthesized SPMs. Natural products, such as purified fish oil could represent another option, although this may not be as potent as SPMs, especially considering the apparent dysregulation of lipid metabolism in LPV patients. Natural products also pose other challenges for drug development, because they may not be patentable products. LPV appears to arise from an extreme of a natural process that provides immune defense to limit vaginal infection (Falsetta et al., 2015; Falsetta et al., 2016; Falsetta et al., 2017; Falsetta et al., 2018; Falsetta et al., 2021; Foster et al., 2015). However, in patients, whether from environmental exposure, genetics, or a combination of these, a "perfect storm" occurs, where patients have enhanced inflammation without the ability to fully resolve this inflammation. This in turn leads to changes in lipid profiles and ultimately the activation of pain signaling pathways.

Fibroblasts are not sensory cells, but they may act as feeder cells to amplify inflammation and pain signals; PGE<sub>2</sub> sensitizes neurons (Reinold et al., 2005; Shapiro, Singer, & Ariel, 2016). Enhanced understanding of the LPV mechanism has uncovered new therapeutic targets and may help to diagnose and assess patients at earlier disease states to limit comorbid conditions and distress. Inflammation may be local in vulvodynia, but even local inflammation has systemic effects, altering brain chemistry and inducing sickness behaviors (Elenkov, Iezzoni, Daly, Harris, & Chrousos, 2005; Elmquist, Scammell, & Saper, 1997; Knorr et al., 2010; Pentreath, Baugh, & Lavin, 1994; Perry, 2004; Perry, 2010; Zhang et al., 2008). Inflammation is a key trigger that initially pushes the snowball down the hill. We have identified several possibilities to prevent or limit inflammation and thus the size of the snowball or prevent its formation entirely. The logical next step is to implement this knowledge clinically through FDA-approved trials, while continuing our investigations of the vulvodynia mechanism.

#### 6. Current knowledge gaps and future directions

Although our mouse model of vulvodynia mimics the human disease in several key ways, it is impossible to recapitulate every aspect of human disease in an animal model, especially when the mechanisms of that disease are not yet fully elucidated. There is strong suspicion that vulvodynia is genetically inherited; a vulvodynia diagnosis is more likely if you have a first degree relative with this disease (Morgan et al., 2016). The data we have collected thus far points to a deficit in the metabolism of AA that favors inflammation while resolution is diminished. There are several well-defined small nucleotide polymorphisms (SNPs) associated with neuropathic pain that occur in the lipoxygenase genes, a key family of enzymes that metabolize AA (Zheng et al., 2020). One of our key future directions is to conduct genomic sequencing to identify potential SNPs or genetic changes that could explain the observed metabolic changes. This could lead to discovery of new screening tools for vulvodynia, help us to better understand the mechanism of disease, and give us additional parameters we can model in mice to more faithfully recapitulate human vulvodynia.

In addition to furthering our mechanistic understanding of disease, we plan to trial topical SPM therapy in vulvodynia patients. The University of Rochester was issued US patent 11,400,057 "Treatment of Vulvar Pain" for exclusive topical use of SPMs and similar preparations (e.g. fish oil) in vulvodynia patients. We are in the process of planning an industry sponsored FDA phase I/II trial using SPMs exclusively licensed to the sponsor. We anticipate that SPM therapy will improve patient reported outcomes, but there are several steps to complete, including formulation, stability programs, safety, and efficacy testing. Unfortunately, only 11% of successful animal trials translate to FDA approved applications in humans (Mogil, 2009). Therefore, while we move towards a clinical trial, we are continuing our mechanistic investigations to leave the door open for other therapeutic options and diagnostic strategies. There is still no objective test to diagnose vulvodynia, which is a significant reason many patients suffer for years before they are diagnosed and treated (Haefner et al., 2005; Stockdale & Lawson, 2014).

#### **Declaration of Competing Interest**

We do not have any conflicts of interest to disclose.

#### Acknowledgments

We have no conflicts to disclose. This work was funded by NIH-NICHD R01 HD092334 and R01 HD069313 and the National Vulvodynia Association. All figures were created with BioRender.com.

#### References

- Akbar, S., Subhan, F., Karim, N., Shahid, M., Ahmad, N., Ali, G., Mahmood, W., & Fawad, K. (2016). 6-Methoxyflavanone attenuates mechanical allodynia and vulvodynia in the streptozotocin-induced diabetic neuropathic pain. *Biomedicine & Pharmacotherapy* 84, 962–971 Epub 2016/10/21. https://doi.org/10.1016/j.biopha.2016.10.017. 27764759.
- Akopians, A. L., & Rapkin, A. J. (2015). Vulvodynia: The role of inflammation in the etiology of localized provoked pain of the vulvar vestibule (Vestibulodynia). Seminars in Reproductive Medicine 33(4), 239–245 Epub 2015/07/02. https://doi.org/10.1055/s-0035-1554919 PubMed PMID: 26132928.
- Ali, G., Subhan, F., Abbas, M., Zeb, J., Shahid, M., & Sewell, R. D. (2015). A streptozotocininduced diabetic neuropathic pain model for static or dynamic mechanical allodynia and vulvodynia: Validation using topical and systemic gabapentin. *Naunyn-Schmiedeberg's Archives of Pharmacology* 388(11), 1129–1140 Epub 2015/07/03. https://doi.org/10.1007/s00210-015-1145-y PubMed PMID: 26134846; PMCID: PMC4619463.
- Alves, C. T., Wei, X. Q., Silva, S., Azeredo, J., Henriques, M., & Williams, D. W. (2014). Candida albicans promotes invasion and colonisation of Candida glabrata in a reconstituted human vaginal epithelium. *The Journal of Infection*. https://doi.org/10. 1016/j.jinf.2014.06.002 (PubMed PMID: 24924556).
- Aman, U., Subhan, F., Shahid, M., Akbar, S., Ahmad, N., Ali, G., ... Sewell, R. D. (2016). *Passiflora incarnata* attenuation of neuropathic allodynia and vulvodynia apropos GABA-ergic and opioidergic antinociceptive and behavioural mechanisms. *BMC Complementary and Alternative Medicine* 16, 77 Epub 2016/02/26. https://doi.org/ 10.1186/s12906-016-1048-6 PubMed PMID: 26912265; PMCID: PMC4765057.
- Andrews, J. C. (2011). Vulvodynia interventions–systematic review and evidence grading. Obstetrical & Gynecological Survey 66(5), 299–315. https://doi.org/10.1097/OGX. 0b013e3182277fb7 (PubMed PMID: 21794194).
- Arnold, L. D., Bachmann, G. A., Rosen, R., Kelly, S., & Rhoads, G. G. (2006). Vulvodynia: Characteristics and associations with comorbidities and quality of life. Obstetrics

Pharmacology & Therapeutics 248 (2023) 108467

and Gynecology 107(3), 617–624. https://doi.org/10.1097/01.AOG.0000199951. 26822.27 PubMed PMID: 16507933; PMCID: 1431685.

- Arriaga-Gomez, E., Kline, J., Emanuel, E., Neamonitaki, N., Yangdon, T., Zacheis, H., ... Chatterjea, D. (2019). Repeated vaginal exposures to the common cosmetic and household preservative methylisothiazolinone induce persistent, mast celldependent genital pain in ND4 mice. *International Journal of Molecular Sciences 20* (21). https://doi.org/10.3390/ijms20215361 Epub 2019/10/31. PubMed PMID: 31661848; PMCID: PMC6862067.
- Awad-Igbaria, Y., Dadon, S., Shamir, A., Livoff, A., Shlapobersky, M., Bornstein, J., & Palzur, E. (2022). Characterization of early inflammatory events leading to provoked vulvodynia development in rats. *Journal of Inflammation Research* 15, 3901–3923 Epub 2022/07/19. https://doi.org/10.2147/JIR.S367193 PubMed PMID: 35845089; PMCID: PMC9286136.
- Baker, D., Peresleni, T., & Kocis, C. (2016). Inflammatory markers in vestibulodynia. Obstetrics and Gynecology 127(Suppl. 1), 1S–2S.
- Bang, S., Yoo, S., Yang, T. J., Cho, H., & Hwang, S. W. (2012). 17(R)-resolvin D1 specifically inhibits transient receptor potential ion channel vanilloid 3 leading to peripheral antinociception. *British Journal of Pharmacology* 165(3), 683–692 Epub 2011/07/02. https://doi.org/10.1111/j.1476-5381.2011.01568.x PubMed PMID: 21718307; PMCID: PMC3315040.
- Bang, S., Yoo, S., Yang, T. J., Cho, H., Kim, Y. G., & Hwang, S. W. (2010). Resolvin D1 attenuates activation of sensory transient receptor potential channels leading to multiple anti-nociception. *British Journal of Pharmacology* 161(3), 707–720 Epub 2010/10/ 01. https://doi.org/10.1111/j.1476-5381.2010.00909.x PubMed PMID: 20880407; PMCID: PMC2990166.
- Barry, C. M., Matusica, D., & Haberberger, R. V. (2019). Emerging evidence of macrophage contribution to hyperinnervation and nociceptor sensitization in vulvodynia. *Frontiers in Molecular Neuroscience* 12(186). https://doi.org/10.3389/fnmol.2019. 00186 Epub 2019/08/27. PubMed PMID: 31447644; PMCID: PMC6691023.
- Berna-Erro, A., Izquierdo-Serra, M., Sepulveda, R. V., Rubio-Moscardo, F., Donate-Macian, P., Serra, S. A., ... Valverde, M. A. (2017). Structural determinants of 5',6'epoxyeicosatrienoic acid binding to and activation of TRPV4 channel. *Scientific Reports* 7(1), 10522. Epub 2017/09/07. https://doi.org/10.1038/s41598-017-11274-1 PubMed PMID: 28874838; PMCID: PMC5585255.
- Bohm-Starke, N. (2010). Medical and physical predictors of localized provoked vulvodynia. Acta Obstetricia et Gynecologica Scandinavica 89(12), 1504–1510. https://doi.org/10.3109/00016349.2010.528368 (PubMed PMID: 21080898).
- Boo, B., Kamath, R., Arriaga-Gomez, E., Landry, J., Emanuel, E., Joo, S., ... Chatterjea, D. (2019). Tetrahydrocannabinol reduces hapten-driven mast cell accumulation and persistent tactile sensitivity in mouse model of allergen-provded localized vulvodynia. *International Journal of Molecular Sciences 20*(9). https://doi.org/10. 3390/ijms20092163 Epub 2019/05/06. PubMed PMID: 31052404; PMCID: PMC6539044.
- Bornstein, J., Goldstein, A. T., Stockdale, C. K., Bergeron, S., Pukall, C., Zolnoun, D., Coady, D., & consensus vulvar pain terminology committee of the International Society for the Study of Vulvovaginal D, International Society for the Study of Women's Sexual H, International Pelvic Pain S (2016). 2015 ISSVD, ISSWSH, and IPPS consensus terminology and classification of persistent vulvar pain and vulvodynia. *The Journal of Sexual Medicine* 13(4), 607–612 Epub 2016/04/06https://doi.org/10.1016/j.jsxm.2016.02. 167. 27045260.
- Bourgeois, C., & Kuchler, K. (2012). Fungal pathogens-a sweet and sour treat for toll-like receptors. Frontiers in Cellular and Infection Microbiology 2, 142. https://doi.org/10. 3389/fcimb.2012.00142 PubMed PMID: 23189270; PMCID: 3504294.
- Buckley, C. D., Gilroy, D. W., & Serhan, C. N. (2014). Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. *Immunity*. 40(3), 315–327. https://doi.org/10.1016/j.immuni.2014.02.009 PubMed PMID: 24656045; PMCID: 4004957.
- Buckley, C. D., Gilroy, D. W., Serhan, C. N., Stockinger, B., & Tak, P. P. (2013). The resolution of inflammation. *Nature Reviews. Immunology* 13(1), 59–66. https://doi.org/10.1038/ nri3362 (PubMed PMID: 23197111).
- Chadha, S., Gianotten, W. L., Drogendijk, A. C., Weijmar Schultz, W. C., Blindeman, L. A., & van der Meijden, W. I. (1998). Histopathologic features of vulvar vestibulitis. International Journal of Gynecological Pathology: Official Journal of the International Society of Gynecological Pathologists 17(1), 7–11 (PubMed PMID: 9475185).
- Chaffin, W. L. (2008). Candida albicans cell wall proteins. Microbiology and Molecular Biology Reviews 72(3), 495–544. https://doi.org/10.1128/MMBR.00032-07 PubMed PMID: 18772287; PMCID: 2546859.
- Chiang, N., & Serhan, C. N. (2017). Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors. *Molecular Aspects of Medicine 58*, 114–129 Epub 2017/03/25. https://doi.org/10.1016/j.mam.2017.03.005 PubMed PMID: 28336292; PMCID: PMC5623601.
- Chiang, N., & Serhan, C. N. (2020). Specialized pro-resolving mediator network: An update on production and actions. *Essays in Biochemistry* 64(3), 443–462 Epub 2020/09/05. https://doi.org/10.1042/EBC20200018. 32885825.
- Chiba, Y., Mizoguchi, I., Mitobe, K., Higuchi, K., Nagai, H., Nishigori, C., ... Yoshimoto, T. (2013). IL-27 enhances the expression of TRAIL and TLR3 in human melanomas and inhibits their tumor growth in cooperation with a TLR3 agonist poly(I:C) partly in a TRAIL-dependent manner. *PLoS One* 8(10), Article e76159. https://doi.org/10. 1371/journal.pone.0076159 PubMed PMID: 24155891; PMCID: 3796519.
- Chiurchiu, V., Leuti, A., Dalli, J., Jacobsson, A., Battistini, L., Maccarrone, M., & Serhan, C. N. (2016). Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses. *Science Translational Medicine* 8(353). https://doi. org/10.1126/scitranslmed.aaf7483 353ra111. Epub 2016/08/26. PubMed PMID: 27559094; PMCID: PMC5149396.
- Cianci, E., Recchiuti, A., Trubiani, O., Diomede, F., Marchisio, M., Miscia, S., ... Romano, M. (2016). Human periodontal stem cells release specialized proresolving mediators

and carry immunomodulatory and prohealing properties regulated by lipoxins. *Stem Cells Translational Medicine* 5(1), 20–32 Epub 2015/11/27. https://doi.org/10. 5966/sctm.2015-0163 PubMed PMID: 26607175; PMCID: PMC4704879.

- Croasdell, A., Thatcher, T. H., Kottmann, R. M., Colas, R. A., Dalli, J., Serhan, C. N., ... Phipps, R. P. (2015). Resolvins attenuate inflammation and promote resolution in cigarette smoke-exposed human macrophages. *American Journal of Physiology. Lung Cellular and Molecular Physiology* 309(8). https://doi.org/10.1152/ajplung.00125.2015 L888–901. Epub 2015/08/25. PubMed PMID: 26301452; PMCID: PMC4609942.
- Dakin, S. G., Colas, R. A., Wheway, K., Watkins, B., Appleton, L., Rees, J., ... Carr, A. J. (2019). Proresolving mediators LXB4 and RvE1 regulate inflammation in stromal cells from patients with shoulder tendon tears. *The American Journal of Pathology* 189(11), 2258–2268 Epub 2019/08/23. https://doi.org/10.1016/j.ajpath.2019.07.011 PubMed PMID: 31437425; PMCID: PMC6876268.
- Damsted-Petersen, C., Boyer, S. C., & Pukall, C. F. (2009). Current perspectives in vulvodynia. Women's Health 5(4), 423–436. https://doi.org/10.2217/whe.09.30 (PubMed PMID: 19586434).
- Danby, C. S., & Margesson, L. J. (2010). Approach to the diagnosis and treatment of vulvar pain. Dermatologic Therapy 23(5), 485–504 Epub 2010/09/28. https://doi.org/10. 1111/j.1529-8019.2010.01352.x PubMed PMID: 20868403.
- Darby, W. G., Grace, M. S., Baratchi, S., & McIntyre, P. (2016). Modulation of TRPV4 by diverse mechanisms. *The International Journal of Biochemistry & Cell Biology* 78, 217–228 Epub 2016/07/19. https://doi.org/10.1016/j.biocel.2016.07.012 PubMed PMID: 27425399.
- Dargie, E., Holden, R. R., & Pukall, C. F. (2017). The vulvar pain assessment questionnaire: Factor structure, preliminary norms, internal consistency, and test-retest reliability. *The Journal of Sexual Medicine* 14(12), 1585–1596 Epub 2017/12/05. https://doi. org/10.1016/j.jsxm.2017.10.072. 29198513.
- Donders, G., & Bellen, G. (2012). Characteristics of the pain observed in the focal vulvodynia syndrome (VVS). *Medical Hypotheses* 78(1), 11–14. https://doi.org/10. 1016/j.mehy.2011.09.030 (PubMed PMID: 22041052).
- Doyle, S. L, & O'Neill, L. A. (2006). Toll-like receptors: From the discovery of NFkappaB to new insights into transcriptional regulations in innate immunity. *Biochemical Pharmacology* 72(9), 1102–1113. https://doi.org/10.1016/j.bcp.2006.07.010 (PubMed PMID: 16930560).
- Elenkov, I. J., Iezzoni, D. G., Daly, A., Harris, A. G., & Chrousos, G. P. (2005). Cytokine dysregulation, inflammation and well-being. *Neuroimmunomodulation*. 12(5), 255–269 Epub 2005/09/17https://doi.org/10.1159/000087104 PubMed PMID: 16166805.
- Elmquist, J. K., Scammell, T. E., & Saper, C. B. (1997). Mechanisms of CNS response to systemic immune challenge: The febrile response. *Trends in Neurosciences* 20(12), 565–570 Epub 1998/01/07. https://doi.org/10.1016/s0166-2236(97)01138-7 PubMed PMID: 9416669.
- Eppsteiner, E., Boardman, L., & Stockdale, C. K. (2014). Vulvodynia. Best Practice & Research. Clinical Obstetrics & Gynaecology 28(7), 1000–1012. https://doi.org/10. 1016/j.bpobgyn.2014.07.009 (PubMed PMID: 25153070).
- Falsetta, M. L., Foster, D. C., Bonham, A. D., & Phipps, R. P. (2017). A review of the available clinical therapies for vulvodynia management and new data implicating proinflammatory mediators in pain elicitation. *BJOG 124*(2), 210–218. https://doi.org/10. 1111/1471-0528.14157 PubMed PMID: 27312009; PMCID: 5164873.
- Falsetta, M. L., Foster, D. C., Woeller, C. F., Pollock, S. J., Bonham, A. D., Haidaris, C. G., & Phipps, R. P. (2016). A role for bradykinin signaling in chronic vulvar pain. *The Journal of Pain: Official Journal of the American Pain Society*. https://doi.org/10.1016/j. jpain.2016.07.007 PMCID: 27544818.
- Falsetta, M. L., Foster, D. C., Woeller, C. F., Pollock, S. J., Bonham, A. D., Haidaris, C. G., ... Phipps, R. P. (2015). Identification of novel mechanisms involved in generating localized vulvodynia pain. *American Journal of Obstetrics and Gynecology*. https://doi.org/ 10.1016/j.ajog.2015.02.002 PMCID: 25683963.
- Falsetta, M. L., Foster, D. C., Woeller, C. F., Pollock, S. J., Bonham, A. D., Piekna-Przybylska, D., , ... Phipps, R. P. (2018). Toll-like receptor signaling contributes to proinflammatory mediator production in localized provoked vulvodynia. *Journal of Lower Genital Tract Disease* 22(1), 52–57. https://doi.org/10.1097/LGT.000000000000364 PubMed PMID: 29271858; PMCID: 5745044.
- Falsetta, M. L., Wood, R. W., Linder, M. A., Bonham, A. D., Honn, K. V., Maddipati, K. R., ... Foster, D. C. (2021). Specialized pro-resolving mediators reduce pro-nociceptive inflammatory mediator production in models of localized provoked vulvodynia. *The Journal of Pain: Official Journal of the American Pain Society* 22(10), 1195–1209 Epub 2021/04/05. https://doi.org/10.1016/j.jpain.2021.03.144 PubMed PMID: 33813057; PMCID: PMC8484336.
- Farage, M., & Maibach, H. (2006). Lifetime changes in the vulva and vagina. Archives of Gynecology and Obstetrics 273(4), 195–202 Epub 2005/10/07. https://doi.org/10. 1007/s00404-005-0079-x. 16208476.
- Farmer, M. A., Taylor, A. M., Bailey, A. L., Tuttle, A. H., MacIntyre, L. C., Milagrosa, Z. E., ... Mogil, J. S. (2011). Repeated vulvovaginal fungal infections cause persistent pain in a mouse model of vulvodynia. *Science Translational Medicine* 3(101). https://doi.org/ 10.1126/scitranslmed.3002613 101ra91. (PubMed PMID: 21937756; PMCID: 3243907).
- Fischer, G. (2004). Management of vulvar pain. Dermatologic Therapy 17(1), 134–149 (PubMed PMID: 14756898).
- Fonseca, F. C., Orlando, R. M., Turchetti-Maia, R. M., & de Francischi, J. N. (2017). Comparative effects of the omega3 polyunsaturated fatty acid derivatives resolvins E1 and D1 and protectin DX in models of inflammation and pain. *Journal of Inflammation Research* 10, 119–133 Epub 2017/09/19. https://doi.org/10.2147/JIR.S142424 PubMed PMID: 28919798; PMCID: PMC5587166.
- Foster, D., Falsetta, M., Woeller, C., Pollock, S., Song, K., Bonham, A., ... Phipps, R. (2015). Site-specific mesenchymal control of inflammatory pain to yeast challenge in vulvodynia afflicted and pain-free women. *Pain.* 156(3), 386–396 (PMCID: 25679469).

- Foster, D. C., Piekarz, K. H., Murant, T. I., LaPoint, R., Haidaris, C. G., & Phipps, R. P. (2007). Enhanced synthesis of proinflammatory cytokines by vulvar vestibular fibroblasts: Implications for vulvar vestibulitis. *American Journal of Obstetrics and Gynecology* 196(4). https://doi.org/10.1016/j.ajog.2006.12.038 346 e1–8. (PubMed PMID: 17403416).
- Friedrich, E. G., Jr. (1983). The vulvar vestibule. The Journal of Reproductive Medicine 28 (11), 773–777 (PubMed PMID: 6655635).
- Gantner, B. N., Simmons, R. M., Canavera, S. J., Akira, S., & Underhill, D. M. (2003). Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. *The Journal of Experimental Medicine* 197(9), 1107–1117. https://doi.org/10.1084/jem. 20021787 PubMed PMID: 12719479; PMCID: 2193968.
- Giraldo, P., von Nowaskonski, A., Gomes, F. A., Linhares, I., Neves, N. A., & Witkin, S. S. (2000). Vaginal colonization by Candida in asymptomatic women with and without a history of recurrent vulvovaginal candidiasis. *Obstetrics and Gynecology* 95(3), 413–416 (PubMed PMID: 10711554).
- Goldstein, A. T., Belkin, Z. R., Krapf, J. M., Song, W., Khera, M., Jutrzonka, S. L., Kim, N. N., Burrows, L. J., & Goldstein, I. (2014). Polymorphisms of the androgen receptor gene and hormonal contraceptive induced provoked vestibulodynia. *The Journal of Sexual Medicine* 11(11), 2764–2771 Epub 2014/09/05. https://doi.org/10.1111/jsm.12668. 25187224.
- Gow, N. A., van de Veerdonk, F. L., Brown, A. J., & Netea, M. G. (2012). Candida albicans morphogenesis and host defence: Discriminating invasion from colonization. *Nature Reviews. Microbiology* 10(2), 112–122. https://doi.org/10.1038/nrmicro2711 PubMed PMID: 22158429; PMCID: 3624162.
- Greenstein, A., Militscher, I., Chen, J., Matzkin, H., Lessing, J. B., & Abramov, L. (2006). Hyperoxaluria in women with vulvar vestibulitis syndrome. *The Journal of Reproductive Medicine* 51(6), 500–502 Epub 2006/07/19. PubMed PMID: 16846091.
- Groysman, V. (2010). Vulvodynia: New concepts and review of the literature. *Dermatologic Clinics* 28(4), 681–696. https://doi.org/10.1016/j.det.2010.07.002 (PubMed PMID: 20883912).
- Haefner, H. K., Collins, M. E., Davis, G. D., Edwards, L., Foster, D. C., Hartmann, E. D., ... Wilkinson, E. J. (2005). The vulvodynia guideline. *Journal of Lower Genital Tract Disease* 9(1), 40–51 (PubMed PMID: 15870521).
- Hammock, B. D., McReynolds, C. B., Wagner, K., Buckpitt, A., Cortes-Puch, I., Croston, G., ... Hwang, S. H. (2021). Movement to the clinic of soluble epoxide hydrolase inhibitor EC5026 as an analgesic for neuropathic pain and for use as a nonaddictive opioid alternative. *Journal of Medicinal Chemistry* 64(4), 1856–1872 Epub 2021/02/09. https:// doi.org/10.1021/acs.jmedchem.0c01886 PubMed PMID: 33550801; PMCID: PMC7917437.
- Hani, U., Shivakumar, H. G., Vaghela, R., Osmani, R. A., & Shrivastava, A. (2015). Candidiasis: A fungal infection–current challenges and progress in prevention and treatment. *Infectious Disorders Drug Targets* 15(1), 42–52 Epub 2015/03/27. https://doi.org/10. 2174/1871526515666150320162036 PubMed PMID: 25809621.
- Harlow, B. L, Abenhaim, H. A., Vitonis, A. F., & Harnack, L. (2008). Influence of dietary oxalates on the risk of adult-onset vulvodynia. *The Journal of Reproductive Medicine* 53 (3), 171–178 Epub 2008/04/30. PubMed PMID: 18441720.
- Harlow, B. L., Caron, R. E., Parker, S. E., Chatterjea, D., Fox, M. P., & Nguyen, R. H. N. (2017). Recurrent yeast infections and vulvodynia: can we believe associations based on selfreported data? *Journal of Women's Health* 26(10), 1069–1076 Epub 2017/07/08. https://doi.org/10.1089/jwh.2016.5777 PubMed PMID: 28686502; PMCID: PMC5651936.
- Harlow, B. L., Kunitz, C. G., Nguyen, R. H., Rydell, S. A., Turner, R. M., & MacLehose, R. F. (2014). Prevalence of symptoms consistent with a diagnosis of vulvodynia: Population-based estimates from 2 geographic regions. *American Journal of Obstetrics and Gynecology 210*(1). https://doi.org/10.1016/j.ajog.2013.09.033 40 e1–8. (PubMed PMID: 24080300; PMCID: 3885163).
- Harlow, B. L., & Stewart, E. G. (2003). A population-based assessment of chronic unexplained vulvar pain: Have we underestimated the prevalence of vulvodynia? *Journal of the American Medical Women's Association* 58(2), 82–88 (PubMed PMID: 12744420).
- Harriott, M. M., Lilly, E. A., Rodriguez, T. E., Fidel, P. L., Jr., & Noverr, M. C. (2010). Candida albicans forms biofilms on the vaginal mucosa. *Microbiology*. 156(Pt 12), 3635–3644. https://doi.org/10.1099/mic.0.039354-0 PubMed PMID: 20705667; PMCID: 3068702.
- Ito, M., Ono, K., Hitomi, S., Nodai, T., Sago, T., Yamaguchi, K., ... Inenaga, K. (2017). Prostanoid-dependent spontaneous pain and PAR2-dependent mechanical allodynia following oral mucosal trauma: involvement of TRPV1, TRPA1 and TRPV4. *Molecular Pain* 13. https://doi.org/10.1177/174806917704138 1744806917704138. Epub 2017/04/07. PubMed PMID: 28381109; PMCID: PMC5407658.
- Jeon, Y., Kim, Y., Shim, B., Yoon, H., Park, Y., Shim, B., ... Lee, D. (2013). A retrospective study of the management of vulvodynia. *Korean Journal of Urology* 54(1), 48–52. https://doi.org/10.4111/kju.2013.54.1.48 PubMed PMID: 23362448; PMCID: 3556554.
- Jeremias, J., Ledger, W. J., & Witkin, S. S. (2000). Interleukin 1 receptor antagonist gene polymorphism in women with vulvar vestibulitis. *American Journal of Obstetrics and Gynecology* 182(2), 283–285 Epub 2000/02/29. https://doi.org/10.1016/s0002-9378 (00)70212-2 PubMed PMID: 10694325.
- Jo, Y. Y., Lee, J. Y., & Park, C. K. (2016). Resolvin E1 inhibits substance P-induced potentiation of TRPV1 in primary sensory neurons. *Mediators of Inflammation*, 5259321 Epub 2016/10/16. https://doi.org/10.1155/2016/5259321 PubMed PMID: 27738388; PMCID: PMC5055963.
- Kalfon, L., Azran, A., Farajun, Y., Golan-Hamu, O., Toben, A., Abramov, L., Yeshaya, A., Yakir, O., Zarfati, D., Falik Zaccai, T. C., & Bornstein, J. (2019). Localized provoked vulvodynia: Association with nerve growth factor and transient receptor potential vanilloid type 1 genes polymorphisms. *Journal of Lower Genital Tract Disease* 23(1), 58–64 Epub 2018/11/13. https://doi.org/10.1097/LGT.000000000000445. 30418350.

- Kaneko, Y., & Szallasi, A. (2014). Transient receptor potential (TRP) channels: a clinical perspective. British Journal of Pharmacology 171(10), 2474–2507 Epub 2013/10/10. https://doi.org/10.1111/bph.12414 PubMed PMID: 24102319; PMCID: PMC4008995.
- Kawabata, A. (2011). Prostaglandin E2 and pain-an update. Biological & Pharmaceutical Bulletin 34(8), 1170-1173 (PubMed PMID: 21804201).
- Kingdon, J. (2009). Vulvodynia: A comprehensive review. Nursing for Women's Health 13 (1), 48–57 quiz 8https://doi.org/10.1111/j.1751-486X.2009.01373.x PubMed PMID: 19207504.
- Kingsberg, S. A., Schaffir, J., Faught, B. M., Pinkerton, J. V., Parish, S. J., Iglesia, C. B., ... Simon, J. A. (2019). Female sexual health: Barriers to optimal outcomes and a roadmap for improved patient-clinician communications. *Journal of Women's Health 28*(4), 432–443 Epub 2019/02/05. https://doi.org/10.1089/jwh.2018.7352 PubMed PMID: 30714849; PMCID: PMC6482896.
- Kjaerstad, M. B., Nielsen, F., Nohr-Jensen, L., Zwisler, S., Brosen, K., & Andersen, H. R. (2010). Systemic uptake of miconazole during vaginal suppository use and effect on CYP1A2 and CYP3A4 associated enzyme activities in women. *European Journal of Clinical Pharmacology* 66(12), 1189–1197 Epub 2010/10/07. https://doi.org/10. 1007/s00228-010-0906-2. 20924570.
- Knorr, C., Marks, D., Gerstberger, R., Muhlradt, P. F., Roth, J., & Rummel, C. (2010). Peripheral and central cyclooxygenase (COX) products may contribute to the manifestation of brain-controlled sickness responses during localized inflammation induced by macrophage-activating lipopeptide-2 (MALP-2). *Neuroscience Letters* 479(2), 107–111 Epub 2010/06/29. https://doi.org/10.1016/j.neulet.2010.05.036 PubMed PMID: 20580659.
- Lawrence, T. (2009). The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harbor Perspectives in Biology 1(6), Article a001651. https://doi.org/10.1101/ cshperspect.a001651 PubMed PMID: 20457564; PMCID: 2882124.
- Leclair, C. M., Goetsch, M. F., Korcheva, V. B., Anderson, R., Peters, D., & Morgan, T. K. (2011). Differences in primary compared with secondary vestibulodynia by immunohistochemistry. *Obstetrics and Gynecology* 117(6), 1307–1313. https://doi.org/10. 1097/AOC.0b013e31821c33dc PubMed PMID: 21606740; PMCID: 3104470.
- Leclair, C. M., Leeborg, N. J., Jacobson-Dunlop, E., Goetsch, M. F., & Morgan, T. K. (2014). CD4-positive T-cell recruitment in primary-provoked localized vulvodynia: Potential insights into disease triggers. *Journal of Lower Genital Tract Disease* 18(2), 195–201. https://doi.org/10.1097/LGT.0b013e3182a55591 (PubMed PMID: 24633162).
- Levy, B. D., & Serhan, C. N. (2014). Resolution of acute inflammation in the lung. Annual Review of Physiology 76, 467–492. https://doi.org/10.1146/annurev-physiol-021113-170408 PubMed PMID: 24313723; PMCID: 4295924.
- Lipsky, M. S., & Taylor, C. (1996). The use of over-the-counter antifungal vaginitis preparations by college students. *Family Medicine* 28(7), 493–495 Epub 1996/07/01. PubMed PMID: 8818620.
- Luo, X., Gu, Y., Tao, X., Serhan, C. N., & Ji, R. R. (2019). Resolvin D5 inhibits neuropathic and inflammatory pain in male but not female mice: Distinct actions of D-series resolvins in chemotherapy-induced peripheral neuropathy. *Frontiers in Pharmacology* 10, 745 Epub 2019/07/25. https://doi.org/10.3389/fphar.2019.00745 PubMed PMID: 31333464; PMCID: PMC6624779.
- Luqman, S., & Pezzuto, J. M. (2010). NFkappaB: A promising target for natural products in cancer chemoprevention. *Phytotherapy Research: PTR 24*(7), 949–963. https://doi.org/ 10.1002/ptr.3171 (PubMed PMID: 20577970).
- Maddipati, K. R. (2020). Non-inflammatory physiology of "inflammatory" mediators unalamation, a new paradigm. *Frontiers in Immunology* 11, 580117 Epub 2020/10/ 30https://doi.org/10.3389/fimmu.2020.580117 PubMed PMID: 33117385; PMCID: PMC7575772.
- Mendling, W., Brasch, J., & German Society for G, Obstetrics, Working Group for I, Infectimmunology in G, Obstetrics, German Society of Dermatology tBoGD, German Speaking Mycological S (2012). Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society. *Mycoses* 55(Suppl. 3), 1–13 Epub 2012/05/02. https://doi.org/10.1111/j.1439-0507. 2012.02185.x PubMed PMID: 22519657.
- Mickle, A. D., Shepherd, A. J., & Mohapatra, D. P. (2015). Sensory TRP channels: The key transducers of nociception and pain. Progress in Molecular Biology and Translational Science 131, 73–118 Epub 2015/03/07. https://doi.org/10.1016/bs.pmbts.2015.01. 002 PubMed PMID: 25744671; PMCID: PMC5903472.
- Mogil, J. S. (2009). Animal models of pain: Progress and challenges. *Nature Reviews. Neuroscience* 10(4), 283–294 Epub 2009/03/05https://doi.org/10.1038/nrn2606 PubMed PMID: 19259101.
- Moore, C., Gupta, R., Jordt, S. E., Chen, Y., & Liedtke, W. B. (2018). Regulation of pain and itch by TRP channels. *Neuroscience Bulletin* 34(1), 120–142 Epub 2017/12/ 29https://doi.org/10.1007/s12264-017-0200-8 PubMed PMID: 29282613; PMCID: PMC5799130.
- Moran, M. M., & Szallasi, A. (2018). Targeting nociceptive transient receptor potential channels to treat chronic pain: current state of the field. *British Journal of Pharmacology* 175(12), 2185–2203 Epub 2017/09/20. https://doi.org/10.1111/bph. 14044 PubMed PMID: 28924972; PMCID: PMC5980611.
- Morgan, T. K., Allen-Brady, K. L., Monson, M. A., Leclair, C. M., Sharp, H. T., & Cannon-Albright, L. A. (2016). Familiality analysis of provoked vestibulodynia treated by vestibulectomy supports genetic predisposition. *American Journal of Obstetrics and Gynecology* 214(5). https://doi.org/10.1016/j.ajog.2015.11.019 609 e1-7. Epub 2015/12/03. PubMed PMID: 26627726.
- Morris, R. W. (1966). Analgesic and local anesthetic activity of dimethyl sulfoxide. Journal of Pharmaceutical Sciences 55(4), 438–440 Epub 1966/04/01. https://doi.org/10. 1002/jps.2600550421 PubMed PMID: 5960300.
- Nett, J. E., Sanchez, H., Cain, M. T., & Andes, D. R. (2010). Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. *The Journal of Infectious Diseases*

202(1), 171–175. https://doi.org/10.1086/651200 PubMed PMID: 20497051; PMCID: 2880631.

- Nguyen, R. H., Turner, R. M., Rydell, S. A., Maclehose, R. F., & Harlow, B. L. (2013). Perceived stereotyping and seeking care for chronic vulvar pain. *Pain Medicine* 14(10), 1461–1467. https://doi.org/10.1111/pme.12151 PubMed PMID: 23742116; PMCID: 4036065.
- NIH (2016). Multidisciplinary research in vulvodynia (R01). Available fromhttps://grants. nih.gov/grants/guide/pa-files/pa-16-102.html.
- Nunns, D., Mandal, D., Byrne, M., McLelland, J., Rani, R., Cullimore, J., ... British Society for the Study of Vulval Disease Guideline G (2010). Guidelines for the management of vulvodynia. *The British Journal of Dermatology* 162(6), 1180–1185. https://doi.org/ 10.1111/j.1365-2133.2010.09684.x (PubMed PMID: 20331460).
- Parish, S. J., & Clayton, A. H. (2007). Sexual medicine education: Review and commentary. *The Journal of Sexual Medicine* 4(2), 259–267 quiz 68. Epub 2007/03/21. https://doi. org/10.1111/j.1743-6109.2007.00430.x PubMed PMID: 17367420.
- Park, C. K., Xu, Z. Z., Liu, T., Lu, N., Serhan, C. N., & Ji, R. R. (2011). Resolvin D2 is a potent endogenous inhibitor for transient receptor potential subtype V1/A1, inflammatory pain, and spinal cord synaptic plasticity in mice: distinct roles of resolvin D1, D2, and E1. *The Journal of Neuroscience* 31(50), 18433–18438 Epub 2011/12/16. https://doi.org/10.1523/JNEUROSCI.4192-11.2011 PubMed PMID: 22171045; PMCID: PMC3242808.
- Payrits, M., Horvath, A., Biro-Suto, T., Erostyak, J., Makkai, G., Saghy, E., ... Szoke, E. (2020). Resolvin D1 and D2 inhibit transient receptor potential Vanilloid 1 and Ankyrin 1 ion channel activation on sensory neurons via lipid raft modification. *International Journal* of Molecular Sciences 21(14). https://doi.org/10.3390/ijms21145019 Epub 2020/07/ 28. PubMed PMID: 32708653; PMCID: PMC7404206.
- Pearson, T., Warren, A. Y., Barrett, D. A., & Khan, R. N. (2009). Detection of EETs and HETEgenerating cytochrome P-450 enzymes and the effects of their metabolites on myometrial and vascular function. *American Journal of Physiology. Endocrinology and Metabolism* 297(3), E647–E656 Epub 2009/06/25. https://doi.org/10.1152/ajpendo. 00227.2009 PubMed PMID: 19549792.
- Pentreath, V. W., Baugh, P. J., & Lavin, D. R. (1994). Sleeping sickness and the central nervous system. *The Onderstepoort Journal of Veterinary Research* 61(4), 369–377 Epub 1994/12/01. PubMed PMID: 7501368.
- Perry, V. H. (2004). The influence of systemic inflammation on inflammation in the brain: Implications for chronic neurodegenerative disease. *Brain, Behavior, and Immunity 18* (5), 407–413 Epub 2004/07/22. https://doi.org/10.1016/j.bbi.2004.01.004 PubMed PMID: 15265532.
- Perry, V. H. (2010). Contribution of systemic inflammation to chronic neurodegeneration. Acta Neuropathologica 120(3), 277–286 Epub 2010/07/21https://doi.org/10.1007/ s00401-010-0722-x PubMed PMID: 20644946.
- Peters, B. M., Palmer, G. E., Nash, A. K., Lilly, E. A., Fidel, P. L., Jr., & Noverr, M. C. (2014). Fungal morphogenetic pathways are required for the hallmark inflammatory response during Candida albicans vaginitis. *Infection and Immunity* 82(2), 532–543. https://doi.org/10.1128/IAI.01417-13 PubMed PMID: 24478069; PMCID: 3911367.
- Pierce, A. N., Zhang, Z., Fuentes, I. M., Wang, R., Ryals, J. M., & Christianson, J. A. (2015). Neonatal vaginal irritation results in long-term visceral and somatic hypersensitivity and increased hypothalamic-pituitary-adrenal axis output in female mice. *Pain 156* (10), 2021–2031 Epub 2015/06/23. https://doi.org/10.1097/j.pain.000000000000264 PubMed PMID: 26098441; PMCID: PMC4578984.
- Poole, D. P., Amadesi, S., Veldhuis, N. A., Abogadie, F. C., Lieu, T., Darby, W., ... Bunnett, N. W. (2013). Protease-activated receptor 2 (PAR2) protein and transient receptor potential vanilloid 4 (TRPV4) protein coupling is required for sustained inflammatory signaling. *The Journal of Biological Chemistry* 288(8), 5790–5802 Epub 2013/01/05. https://doi.org/10.1074/jbc.M112.438184 PubMed PMID: 23288842; PMCID: PMC3581372.
- Pukall, C. F., Goldstein, A. T., Bergeron, S., Foster, D., Stein, A., Kellogg-Spadt, S., & Bachmann, G. (2016). Vulvodynia: Definition, prevalence, impact, and pathophysiological factors. *The Journal of Sexual Medicine* 13(3), 291–304 Epub 2016/03/06. https://doi.org/10.1016/j.jsxm.2015.12.021. 26944461.
- Ramirez De Knott, H. M., McCormick, T. S., Do, S. O., Goodman, W., Ghannoum, M. A., Cooper, K. D., & Nedorost, S. T. (2005). Cutaneous hypersensitivity to Candida albicans in idiopathic vulvodynia. *Contact Dermatilis* 53(4), 214–218. https://doi.org/10.1111/ j.0105-1873.2005.00685.x (PubMed PMID: 16191018).
- Rangappa, S., Shankar, V. K., Jo, S., Repka, M. A., & Murthy, S. N. (2021). Chemotherapeutic agent-induced vulvodynia, an experimental model. AAPS PharmSciTech 22(3), 95 Epub 2021/03/10https://doi.org/10.1208/s12249-021-01969-0. 33686480.
- Reed, B. D., Harlow, S. D., Plegue, M. A., & Sen, A. (2015). Genetic differences may reflect differences in susceptibility to vulvodynia in general or in spontaneous remission propensity. *The Journal of Sexual Medicine* 12(2), 578 Epub 2014/11/27https://doi. org/10.1111/jsm.12775 PubMed PMID: 25424503.
- Reed, B. D., Harlow, S. D., Sen, A., Edwards, R. M., Chen, D., & Haefner, H. K. (2012). Relationship between vulvodynia and chronic comorbid pain conditions. *Obstetrics and Gynecology* 120(1), 145–151. https://doi.org/10.1097/AOG.0b013e31825957cf PubMed PMID: 22914403; PMCID: 3566870.
- Reed, B. D., Harlow, S. D., Sen, A., Legocki, L. J., Edwards, R. M., Arato, N., & Haefner, H. K. (2012). Prevalence and demographic characteristics of vulvodynia in a populationbased sample. *American Journal of Obstetrics and Gynecology* 206(2). https://doi.org/ 10.1016/j.ajog.2011.08.012 170 e1–9. (PubMed PMID: 21963307; PMCID: 3779055).
- Reed, B. D., Legocki, L. J., Plegue, M. A., Sen, A., Haefner, H. K., & Harlow, S. D. (2014). Factors associated with vulvodynia incidence. *Obstetrics and Gynecology* 123(2 Pt 1), 225–231. https://doi.org/10.1097/AOG.00000000000066 PubMed PMID: 24402591; PMCID: 3913176.
- Reed, B. D., Plegue, M. A., Sen, A., Haefner, H. K., Siddiqui, J., & Remick, D. G. (2018). Nerve growth factor and selected cytokines in women with and without vulvodynia. *Journal*

of Lower Genital Tract Disease 22(2), 139–146 Epub 2018/03/24. https://doi.org/10. 1097/LGT.000000000000377. 29570566.

- Reinold, H., Ahmadi, S., Depner, U. B., Layh, B., Heindl, C., Hamza, M., ... Zeilhofer, H. U. (2005). Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype. *The Journal of Clinical Investigation* 115(3), 673–679. https://doi. org/10.1172/JCI23618 PubMed PMID: 15719070; PMCID: 548700.
- Rosen, N. O., Dawson, S. J., Brooks, M., & Kellogg-Spadt, S. (2019). Treatment of vulvodynia: Pharmacological and non-pharmacological approaches. *Drugs.* 79(5), 483–493 Epub 2019/03/09. https://doi.org/10.1007/s40265-019-01085-1. 30847806.
- Rubin, E. S., Rullo, J., Tsai, P., Criniti, S., Elders, J., Thielen, J. M., & Parish, S. J. (2018). Best practices in North American pre-clinical medical education in sexual history taking: Consensus from the summits in medical education in sexual health. *The Journal of Sexual Medicine* 15(10), 1414–1425 Epub 2018/10/10. https://doi.org/10.1016/j. jsxm.2018.08.008. 30297093.
- Sadownik, L. A. (2014). Etiology, diagnosis, and clinical management of vulvodynia. International Journal of Women's Health 6, 437–449. https://doi.org/10.2147/IJWH. S37660 PubMed PMID: 24833921; PMCID: 4014358.
- Serhan, C. N. (2014). Pro-resolving lipid mediators are leads for resolution physiology. *Nature*. 510(7503), 92–101. https://doi.org/10.1038/nature13479 PubMed PMID: 24899309; PMCID: 4263681.
- Serhan, C. N. (2017a). Treating inflammation and infection in the 21st century: New hints from decoding resolution mediators and mechanisms. *The FASEB Journal* 31(4), 1273–1288 Epub 2017/01/15. https://doi.org/10.1096/fj.201601222R PubMed PMID: 28087575; PMCID: PMC5349794.
- Serhan, C. N. (2017b). Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology. *Molecular Aspects of Medicine* 58, 1–11 Epub 2017/03/07. https://doi.org/10.1016/j.mam.2017.03.001 PubMed PMID: 28263773; PMCID: PMC5582020.
- Serhan, C. N., Chiang, N., & Dalli, J. (2015). The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. *Seminars in Immunology*. https:// doi.org/10.1016/j.smim.2015.03.004 (PubMed PMID: 25857211).
- Serhan, C. N., Chiang, N., & Dalli, J. (2018). New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration. *Molecular Aspects of Medicine* 64, 1–17 Epub 2017/08/15. https://doi.org/10.1016/j.mam.2017.08.002 PubMed PMID: 28802833; PMCID: PMC5832503.
- Serhan, C. N., Chiang, N., Dalli, J., & Levy, B. D. (2014). Lipid mediators in the resolution of inflammation. *Cold Spring Harbor Perspectives in Biology* 7(2). https://doi.org/10.1101/ cshperspect.a016311 a016311. Epub 2014/11/02. PubMed PMID: 25359497; PMCID: PMC4315926.
- Serhan, C. N., Dalli, J., Karamnov, S., Choi, A., Park, C. K., Xu, Z. Z., ... Petasis, N. A. (2012). Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. *The FASEB Journal* 26(4), 1755–1765 Epub 2012/01/19. https://doi. org/10.1096/fj.11-201442 PubMed PMID: 22253477; PMCID: PMC3316905.
- Shapiro, H., Singer, P., & Ariel, A. (2016). Beyond the classic eicosanoids: Peripherallyacting oxygenated metabolites of polyunsaturated fatty acids mediate pain associated with tissue injury and inflammation. *Prostaglandins, Leukotrienes, and Essential Fatty Acids* 111, 45–61 Epub 2016/04/14. https://doi.org/10.1016/j.plefa.2016.03.001 PubMed PMID: 27067460.
- Shindel, A. W., & Parish, S. J. (2013). Sexuality education in North American medical schools: Current status and future directions. *The Journal of Sexual Medicine* 10(1), 3–17 quiz 8. Epub 2013/01/25. https://doi.org/10.1111/j.1743-6109.2012.02987.x PubMed PMID: 23343168.
- Simonelli, C., Eleuteri, S., Petruccelli, F., & Rossi, R. (2014). Female sexual pain disorders: Dyspareunia and vaginismus. *Current Opinion in Psychiatry* 27(6), 406–412 Epub 2014/09/12. https://doi.org/10.1097/YCO.000000000000098 PubMed PMID: 25211497.
- Solursh, D. S., Ernst, J. L., Lewis, R. W., Prisant, L. M., Mills, T. M., Solursh, L. P., ... Salazar, W. H. (2003). The human sexuality education of physicians in North American medical schools. *International Journal of Impotence Research* 15(Suppl. 5), S41–S45 Epub 2003/10/11. https://doi.org/10.1038/sji.jijr.3901071 PubMed PMID: 14551576.
- Spoelstra, S. K., Dijkstra, J. R., van Driel, M. F., & Weijmar Schultz, W. C. (2011). Long-term results of an individualized, multifaceted, and multidisciplinary therapeutic approach to provoked vestibulodynia. *The Journal of Sexual Medicine* 8(2), 489–496. https://doi. org/10.1111/j.1743-6109.2010.01941.x (PubMed PMID: 20646179).
- Stenson, A. L. (2017). Vulvodynia: Diagnosis and management. Obstetrics and Gynecology Clinics of North America 44(3), 493–508 Epub 2017/08/06. https://doi.org/10.1016/j. ogc.2017.05.008 PubMed PMID: 28778645.
- Stockdale, C. K., & Lawson, H. W. (2014). 2013 Vulvodynia guideline update. Journal of Lower Genital Tract Disease 18(2), 93–100 Epub 2014/03/19. https://doi.org/10. 1097/LGT.00000000000021. 24633161.
- Taff, H. T., Nett, J. E., Zarnowski, R., Ross, K. M., Sanchez, H., Cain, M. T., ... Andes, D. R. (2012). A Candida biofilm-induced pathway for matrix glucan delivery: Implications for drug resistance. *PLoS Pathogens* 8(8), Article e1002848. https://doi.org/10.1371/ journal.ppat.1002848 PubMed PMID: 22876186; PMCID: 3410897.
- Tao, X., Lee, M. S., Donnelly, C. R., & Ji, R. R. (2020). Neuromodulation, specialized proresolving mediators, and resolution of pain. *Neurotherapeutics* 17(3), 886–899 Epub 2020/07/23. https://doi.org/10.1007/s13311-020-00892-9 PubMed PMID: 32696274; PMCID: PMC7609770.
- Thomson, S. J., Askari, A., & Bishop-Bailey, D. (2012). Anti-inflammatory effects of epoxyeicosatrienoic acids. *International Journal of Vascular Medicine*, 605101 Epub 2012/08/01. https://doi.org/10.1155/2012/605101 PubMed PMID: 22848834; PMCID: PMC3405717.
- Tieu, K. D., & MacGregor, J. L. (2011). Successful treatment of vulvodynia with botulinum toxin A. Archives of Dermatology 147(2), 251–252. https://doi.org/10.1001/ archdermatol.2010.443 (PubMed PMID: 21339463).

- Tommola, P., Butzow, R., Unkila-Kallio, L., Paavonen, J., & Meri, S. (2015). Activation of vestibule-associated lymphoid tissue in localized provoked vulvodynia. *American Journal of Obstetrics and Gynecology* 212(4). https://doi.org/10.1016/j.ajog.2014.10. 1098 476 e1–8. (PubMed PMID: 25448516).
- Tommola, P., Unkila-Kallio, L., & Paavonen, J. (2010). Surgical treatment of vulvar vestibulitis: A review. Acta Obstetricia et Gynecologica Scandinavica 89(11), 1385–1395. https://doi.org/10.3109/00016349.2010.512071 (PubMed PMID: 20955094).
- Tommola, P., Unkila-Kallio, L., & Paavonen, J. (2011). Long-term follow up of posterior vestibulectomy for treating vulvar vestibulitis. Acta Obstetricia et Gynecologica Scandinavica 90(11), 1225–1231. https://doi.org/10.1111/j.1600-0412.2011.01248.x (PubMed PMID: 21793812).
- Tommola, P., Unkila-Kallio, L., & Paavonen, J. (2012). Long-term well-being after surgical or conservative treatment of severe vulvar vestibulitis. Acta Obstetricia et Gynecologica Scandinavica 91(9), 1086–1093. https://doi.org/10.1111/j.1600-0412. 2012.01466.x (PubMed PMID: 22621618).
- Tommola, P., Unkila-Kallio, L., Paetau, A., Meri, S., Kalso, E., & Paavonen, J. (2016). Immune activation enhances epithelial nerve growth in provoked vestibulodynia. *American Journal of Obstetrics and Gynecology 215*(6). https://doi.org/10.1016/j.ajog.2016.07. 037 768 e1- e8. Epub 2016/07/28. PubMed PMID: 27457118.
- Vriens, J., Owsianik, G., Fisslthaler, B., Suzuki, M., Janssens, A., Voets, T., ... Nilius, B. (2005). Modulation of the Ca2 permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium. *Circulation Research* 97(9), 908–915 Epub 2005/09/24. https://doi.org/10.1161/01.RES.0000187474.47805.30 PubMed PMID: 16179585.
- Vulvar Pain [Internet]2000–2023. cited March 13. Available fromhttps://reporter.nih.gov/ (2023)..
- Wang, C., Ning, L. P., Wang, Y. H., Zhang, Y., Ding, X. L., Ge, H. Y., ... Yue, S. W. (2011). Nuclear factor-kappa B mediates TRPV4-NO pathway involved in thermal hyperalgesia following chronic compression of the dorsal root ganglion in rats. *Behavioural Brain Research* 221(1), 19–24 Epub 2011/03/02. https://doi.org/10.1016/j.bbr.2011.02. 028 PubMed PMID: 21356247.
- Wesselmann, U., Bonham, A., & Foster, D. (2014). Vulvodynia: Current state of the biological science. *Pain.* https://doi.org/10.1016/j.pain.2014.05.010 (PubMed PMID: 24858303).

- Wu, C., Goldstein, A., Klebanoff, J. S., & Moawad, G. N. (2019). Surgical management of neuroproliferative-associated vestibulodynia: a tutorial on vestibulectomy with vaginal advancement flap. *American Journal of Obstetrics and Gynecology 221*(5). https:// doi.org/10.1016/j.ajog.2019.08.009 525 e1- e2. Epub 2019/08/14. PubMed PMID: 31408632.
- Wylie, K. R. (2017). Vulvodynia a painful condition; an inflammatory process? BJOG: An International Journal of Obstetrics and Gynaecology 124(2), 219 Epub 2016/11/20. https://doi.org/10.1111/1471-0528.14415. 27860096.
- Yu, Z., Xu, F., Huse, L. M., Morisseau, C., Draper, A. J., Newman, J. W., Parker, C., Graham, L., Engler, M. M., Hammock, B. D., Zeldin, D. C., & Kroetz, D. L. (2000). Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. *Circulation Research* 87(11), 992–998 Epub 2000/11/25. https://doi.org/10.1161/01.res.87.11. 992, 11090543.
- Zanotta, N., Campisciano, G., Scrimin, F., Ura, B., Marcuzzi, A., Vincenti, E., Crovella, S., & Comar, M. (2018). Cytokine profiles of women with vulvodynia: Identification of a panel of pro-inflammatory molecular targets. *European Journal of Obstetrics, Gynecol*ogy, and Reproductive Biology 226, 66–70 Epub 2018/06/01. https://doi.org/10.1016/j. ejogrb.2018.05.035. 29852336.
- Zhang, H., Ching, S., Chen, Q., Li, Q., An, Y., & Quan, N. (2008). Localized inflammation in peripheral tissue signals the CNS for sickness response in the absence of interleukin-1 and cyclooxygenase-2 in the blood and brain. *Neuroscience* 157(4), 895–907 Epub 2008/10/28. https://doi.org/10.1016/j.neuroscience.2008.09.038 PubMed PMID: 18950689; PMCID: PMC2642963.
- Zhang, L., Terrando, N., Xu, Z. Z., Bang, S., Jordt, S. E., Maixner, W., ... Ji, R. R. (2018). Distinct analgesic actions of DHA and DHA-derived specialized pro-resolving mediators on post-operative pain after bone fracture in mice. *Frontiers in Pharmacology* 9, 412 Epub 2018/05/17. https://doi.org/10.3389/fphar.2018.00412 PubMed PMID: 29765320; PMCID: PMC5938385.
- Zheng, Z., Li, Y., Jin, G., Huang, T., Zou, M., & Duan, S. (2020). The biological role of arachidonic acid 12-lipoxygenase (ALOX12) in various human diseases. *Biomedicine & Pharmacotherapy* 129, 110354 Epub 2020/06/17. https://doi.org/10.1016/j.biopha. 2020.110354 PubMed PMID: 32540644.
- Zosmer, A., Elder, M. G., & Sullivan, M. H. (2002). The production of progesterone and 5,6epoxyeicosatrienoic acid by human granulosa cells. *The Journal of Steroid Biochemistry* and Molecular Biology 81(4–5), 369–376 Epub 2002/10/04. https://doi.org/10.1016/ s0960-0760(02)00116-4. 12361727.